Evidence map›Paper›PMID 41804221›Full record

ArticleThe FEBS journal2026

T-bet

Lijun Yang, Yujia Wang, Mingyang Li, Zhexiong Lian, Zhinan Yin, Jie Hao, Xiuyuan Sun, Rong Jin, Qing Ge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lijun YangDepartment of Immunology, NHC Key Laboratory of Medical Immunology (Peking University), Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, School of Basic Medical Sciences, Peking University, Beijing, China.
Yujia WangDepartment of Immunology, NHC Key Laboratory of Medical Immunology (Peking University), Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, School of Basic Medical Sciences, Peking University, Beijing, China.
Mingyang LiImmunology Research Center, Beijing Clinical Research Institute, Beijing Friendship Hospital, Capital Medical University, China.
Zhexiong LianGuangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Zhinan YinGuangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital Affiliated with Jinan University, Jinan University, Zhuhai, Guangdong, China.
Jie HaoDepartment of Immunology, NHC Key Laboratory of Medical Immunology (Peking University), Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, School of Basic Medical Sciences, Peking University, Beijing, China.
Xiuyuan SunDepartment of Immunology, NHC Key Laboratory of Medical Immunology (Peking University), Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, School of Basic Medical Sciences, Peking University, Beijing, China.
Rong JinDepartment of Immunology, NHC Key Laboratory of Medical Immunology (Peking University), Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, School of Basic Medical Sciences, Peking University, Beijing, China.ORCID https://orcid.org/0000-0002-5666-9497
Qing GeDepartment of Immunology, NHC Key Laboratory of Medical Immunology (Peking University), Medicine Innovation Center for Fundamental Research on Major Immunology-Related Diseases, School of Basic Medical Sciences, Peking University, Beijing, China.ORCID https://orcid.org/0000-0002-6231-4545

Funding

Beijing Life Science Academy 2024600CC0080 RJBeijing Natural Science Foundation 7242087 QGHenan Medical Science and Technology research Program joint construction project LHGJ20230265Key Support Project of Guo Zhong Health Care of China General Technology Group GZKJ-KJXX-QTHT-20230626National Key Research and Development Program of China 2023YFB3507002 RJNational Natural Science Foundation of China 32270935QGNational Natural Science Foundation of China 32571042the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2018PT31039
6 · The paper itself

Abstract

Neonatal regulatory T (Treg) cells in secondary lymphoid organs have greater proliferative capacity and more potent suppressive functions than adult Treg cells. However, the phenotypic and functional features of Tregs in neonatal nonlymphoid organs are not well understood. Our prior work demonstrated that thymus-derived Treg cells entering the neonatal mouse liver enhance immune tolerance and periportal liver maturation. Compared to splenic Treg cells, these hepatic Tregs have faster turnover and superior suppression of naïve T-cell proliferation. To further define this population, we conducted single-cell transcriptomic and immunophenotypic analyses of liver- and spleen-derived Tregs from neonatal and adult mice. Our analysis revealed a distinct T-box transcription factor Tbx21 (T-bet)

Indexed as

Interferon-gammaInterleukin-27LiverT-Box Domain ProteinsT-Lymphocytes, RegulatoryAnimalsAnimals, NewbornAntigens, CDApyraseCell ProliferationInterleukinsMiceMice, Inbred C57BLReceptors, CXCR3SpleenT-bet Transcription FactorAntigens, CDApyraseCD39 antigenCxcr3 protein, mouseIl27 protein, mouseInterferon-gammaInterleukin-27InterleukinsReceptors, CXCR3T-bet Transcription FactorT-Box Domain ProteinsIFN‐γIL‐27neonatal liverRegulatory T cellsT‐bet

Identifiers

PMID41804221
PMCPMC13440582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.